A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.
Saved in:
| Title: | A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis. |
|---|---|
| Authors: | Tuscano JM; Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA.; Section of Hematology and Oncology, Veterans Administration Northern California Healthcare System, Mather, CA., Othman T; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA., Frankel P; Department of Biostatistics, City of Hope, Duarte, CA., Ruel C; Department of Biostatistics, City of Hope, Duarte, CA., Poh C; Department of Biostatistics, City of Hope, Duarte, CA., Herbert S; Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA., Maverakis E; Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA., Merleev AA; Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA., Luxardi G; Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA., Abedi M; Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA., Ranganathan R; Division of Hematology and Oncology University of Southern California, Los Angeles, CA., Modi D; Division of Hematology and Oncology, Karmanos Cancer Institute, Detroit, MI., Zain J; Department of Biostatistics, City of Hope, Duarte, CA., Budde EL; Department of Biostatistics, City of Hope, Duarte, CA., Mei M; Department of Biostatistics, City of Hope, Duarte, CA., Rosenberg AS; Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA., Hoeg RT; Division of Malignant Hematology Cellular Therapy and Transplantation, University of California Davis, Sacramento, CA., Costello C; Division of Hematology and Oncology, University of California San Diego, La Jolla, CA., Foss FM; Section of Medical Oncology, Yale Cancer Center, New Haven, CT., William BM; Department of Hematology and Oncology, The Ohio State University, Columbus, OH., Holland HK; Department of Blood and Marrow Transplantation at Northside Hospital, Atlanta, GA., Sharon E; Department of Medicine, Dana-Farber Cancer Institute, Boston, MA., Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Danilov AV; Department of Biostatistics, City of Hope, Duarte, CA., Newman E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD. |
| Source: | Blood advances [Blood Adv] 2026 Feb 24; Vol. 10 (4), pp. 1153-1162. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
